Drug Trial Radar · NCT07140484
Sotatercept in Pulmonary Arterial Hypertension
Last checked: Nov 20, 2026Latest source record: Nov 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
27
Planned (sponsor's estimate)
Start
Oct 6, 2025
Primary completion
Jan 1, 2029
Study completion Jan 1, 2030
Sponsor
- Lead sponsor
- University of AlbertaAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Merck Canada Inc.; Alberta Health services
- First posted
- Aug 24, 2025
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical trial is to determine whether sotatercept is effective in improving diffusing capacity in patients with pulmonary arterial hypertension. Participants will be asked to: * Take Sotatercept every 21 days (±3 days) * Each participant will be enrolled in the study for 29 Weeks * Visit the clinic 18 times * Have a physical exam * Perform assessments of lung function and exercise tests * Have an ultrasound of their heart * Have blood draws done at regular intervals The main objectives of the study are: Primary objective: To assess whether sotatercept will improve recruitment of diffusing membrane capacity (DM) with exercise. Secondary objective: To identify components of the diffusing capacity that respond to treatment with sotatercept in pulmonary arterial hypertension.
Conditions
- Pulmonary Artery Hypertension
Interventions
SotaterceptDrug
0.7mg/kg
Primary outcomes
What the sponsor says the trial is designed to measure.
- Lung diffusing capacityTime frame: 6 weeks post starting treatment
- Lung diffusing capacityTime frame: 23 weeks post starting treatment
- Diffusing membrane capacity (Dm)Time frame: 6 weeks post starting treatment
- Diffusing membrane capacity (Dm)Time frame: 23 weeks post starting treatment
- Pulmonary capillary blood volume (Vc)Time frame: 6 weeks post starting treatment
- Pulmonary capillary blood volume (Vc)Time frame: 23 weeks post starting treatment
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Clinical Physiology Laboratory
Edmonton, Alberta, Canada · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.